Ignacio Garrido-Laguna, MD, PhD is an Associate Professor of oncology (tenure-track) at the University of Utah School of Medicine and a member of the Experimental Therapeutics Program at Huntsman Cancer Institute (HCI). At HCI, he sees patients with gastrointestinal cancers and patients enrolled in Phase I trials.   Garrido-Laguna’s primary research interest is pancreatic ductal adenocarcinoma (PDA). Dr.Garrido-Laguna and Dr.Kadrmas are co-PI in R21CA182977 to evaluate the role of FDG/FLT/Oxygen labelled water PET to predict response to nab-paclitaxel plus gemcitabine in patients with borderline resectable or locally advanced pancreatic cancer undergoing induction chemotherapy. He is PI of multiple clinical trials including novel therapies such as immunotherapies that hold promise in the treatment of this disease.   A native from Spain, Dr.Garrido-Laguna was a clinical fellow in the Phase I program at the University of Texas MD Anderson Cancer Center before joining HCI. He completed his postdoctoral fellowship in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. While at Hopkins, he worked extensively in patient derived xenografts. His research showed that stroma (tissue around the tumor that gives nutritioin to cancer cells) is involved in resistance to chemotherapy in pancreatic cancer. Garrido-Laguna finished his internship and residency in Internal Medicine-Medical oncology at Hospital Universitario 12 de Octubre in Madrid, Spain. Garrido-Laguna received his medical degree from the School of Medicine of Universidad de Navarra, Pamplona, Spain.

Pancreatic cancer Clinical Trials, Phase I Preclinical models of cancer as platforms for drug development Colon Cancer Early Drug Development High-throughput Techniques